Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Deep Diving Into the Next Wave of Bioconjugate Design & Mechanisms to Overcome Payload Resistance & Enhance ADC Therapeutic Properties

By | 8 June 2026

Breaking down the exciting landscape of novel drug conjugate design and mechanisms of action
Exploring emerging trends across conjugate design and targets
Spotlighting novel conjugate innovation across multi payload ADCs, bispecific ADCs and degrader antibody conjugates